-
公开(公告)号：US20050119203A1
公开(公告)日：2005-06-02
申请号：US10494333
申请日：2002-10-31
申请人： Andreas Steinbrecher , Gerhard Giegerich , Ingo Kleiter , Markus Horn , Rainer Appel , Roland Kreutzer , Stefan Limmer , Hans-Peter Vornlocher
发明人： Andreas Steinbrecher , Gerhard Giegerich , Ingo Kleiter , Markus Horn , Rainer Appel , Roland Kreutzer , Stefan Limmer , Hans-Peter Vornlocher
IPC分类号： A61K38/00 , C12N15/113 , A61K48/00
CPC分类号： C12N15/113 , A61K38/00 , A61K2039/505 , C12N2310/14 , C12N2310/315 , C12N2310/53
摘要： The present invention relates to the use of a specific inhibitor of Smad7 expression or function for the preparation of a pharmaceutical composition for the prevention, amelioration or treatment of a disease of the central nervous system and/or diseases related and/or caused by said disease of the central nervous system. Furthermore, methods for preventing, ameliorating and/or treating such diseases are disclosed.
摘要翻译： 本发明涉及Smad7表达或功能的特异性抑制剂在制备用于预防，改善或治疗中枢神经系统疾病和/或所述疾病相关和/或引起的疾病的药物组合物中的用途 的中枢神经系统。 此外，公开了用于预防，改善和/或治疗这些疾病的方法。
-
公开(公告)号：US07700572B2
公开(公告)日：2010-04-20
申请号：US10494333
申请日：2002-10-31
申请人： Andreas Steinbrecher , Gerhard Giegerich , Ingo Kleiter , Markus Horn , Rainer Apfel , Roland Kreutzer , Stefan Limmer , Hans-Peter Vornlocher
发明人： Andreas Steinbrecher , Gerhard Giegerich , Ingo Kleiter , Markus Horn , Rainer Apfel , Roland Kreutzer , Stefan Limmer , Hans-Peter Vornlocher
CPC分类号： C12N15/113 , A61K38/00 , A61K2039/505 , C12N2310/14 , C12N2310/315 , C12N2310/53
摘要： The present invention relates to the use of a specific inhibitor of Smad7 expression or function for the preparation of a pharmaceutical composition for the prevention, amelioration or treatment of a disease of the central nervous system and/or diseases related and/or caused by said disease of the central nervous system. Furthermore, methods for preventing, ameliorating and/or treating such diseases are disclosed.
摘要翻译： 本发明涉及Smad7表达或功能的特异性抑制剂在制备用于预防，改善或治疗中枢神经系统疾病和/或所述疾病相关和/或引起的疾病的药物组合物中的用途 的中枢神经系统。 此外，公开了用于预防，改善和/或治疗这些疾病的方法。
-
公开(公告)号：US20110207795A1
公开(公告)日：2011-08-25
申请号：US12565629
申请日：2009-09-23
申请人： Andreas Steinbrecher , Gerhard Giegerich , Ingo Kleiter , Markus Horn , Rainer Apfel , Roland Kreutzer , Stefan Limmer , Hans-Peter Vornlocher
发明人： Andreas Steinbrecher , Gerhard Giegerich , Ingo Kleiter , Markus Horn , Rainer Apfel , Roland Kreutzer , Stefan Limmer , Hans-Peter Vornlocher
IPC分类号： A61K31/7088 , A61P25/00
CPC分类号： C12N15/113 , A61K38/00 , A61K2039/505 , C12N2310/14 , C12N2310/315 , C12N2310/53
摘要： The present invention relates to the use of a specific inhibitor of Smad7 expression or function for the preparation of a pharmaceutical composition for the prevention, amelioration or treatment of a disease of the central nervous system and/or diseases related and/or caused by said disease of the central nervous system. Furthermore, methods for preventing, ameliorating and/or treating such diseases are disclosed.
摘要翻译： 本发明涉及Smad7表达或功能的特异性抑制剂在制备用于预防，改善或治疗中枢神经系统疾病和/或所述疾病相关和/或引起的疾病的药物组合物中的用途 的中枢神经系统。 此外，公开了用于预防，改善和/或治疗这些疾病的方法。
-
4.发明申请Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene 有权双链RNA（dsRNA）和用于抑制融合基因表达的方法公开(公告)号：US20070185050A1
公开(公告)日：2007-08-09
申请号：US11656349
申请日：2007-01-22
CPC分类号： C12N15/1135 , A61K38/00 , C12N2310/14 , C12N2310/3183 , C12N2310/53
摘要： The present invention relates to the specific inhibition of expression of a fusion gene in mammals using a short double stranded RNA. The dsRNA is approximately 19-24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia.
摘要翻译： 本发明涉及使用短双链RNA的哺乳动物中融合基因的表达的特异性抑制。 dsRNA长度为约19-24个核苷酸，并且具有与目标基因的至少一部分互补的核苷酸序列。 本发明的dsRNA可用于治疗由染色体畸变引起的疾病，特别是恶性疾病如淋巴瘤和白血病。
-
5.发明授权Double-stranded RNA (DSRNA) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene 有权双链RNA（DSRNA）及其抑制AML-1 / MTG8融合基因表达的方法公开(公告)号：US07196184B2
公开(公告)日：2007-03-27
申请号：US10349320
申请日：2003-01-22
CPC分类号： C12N15/1135 , A61K38/00 , C12N2310/14 , C12N2310/3183 , C12N2310/53
摘要： The present invention relates to the specific inhibition of expression of a fusion gene in mammals using a short double stranded RNA. The dsRNA is approximately 19–24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia.
摘要翻译： 本发明涉及使用短双链RNA的哺乳动物中融合基因的表达的特异性抑制。 dsRNA长度为约19-24个核苷酸，并且具有与目标基因的至少一部分互补的核苷酸序列。 本发明的dsRNA可用于治疗由染色体畸变引起的疾病，特别是恶性疾病如淋巴瘤和白血病。
-
6.发明授权Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene 有权双链RNA（dsRNA）和用于抑制融合基因表达的方法公开(公告)号：US07846907B2
公开(公告)日：2010-12-07
申请号：US11656349
申请日：2007-01-22
IPC分类号： A61K48/00
CPC分类号： C12N15/1135 , A61K38/00 , C12N2310/14 , C12N2310/3183 , C12N2310/53
摘要： The present invention relates to the specific inhibition of expression of a fusion gene in mammals using a short double stranded RNA. The dsRNA is approximately 19-24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia.
摘要翻译： 本发明涉及使用短双链RNA的哺乳动物中融合基因的表达的特异性抑制。 dsRNA长度为约19-24个核苷酸，并且具有与目标基因的至少一部分互补的核苷酸序列。 本发明的dsRNA可用于治疗由染色体畸变引起的疾病，特别是恶性疾病如淋巴瘤和白血病。
-
7.发明授权公开(公告)号：US07473525B2
公开(公告)日：2009-01-06
申请号：US10384260
申请日：2003-03-07
申请人： Roland Kreutzer , Stefan Limmer , Hans-Peter Vornlocher , Philipp Hadwiger , Anke Geick , Matthias Ocker , Christoph Herold , Detlef Schuppan
发明人： Roland Kreutzer , Stefan Limmer , Hans-Peter Vornlocher , Philipp Hadwiger , Anke Geick , Matthias Ocker , Christoph Herold , Detlef Schuppan
CPC分类号： C12N15/113 , C12N15/1131 , C12N2310/152 , C12N2310/315 , C12N2310/3183 , C12N2310/33 , C12N2310/351 , C12N2310/3511 , C12N2310/53
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising a complementary RNA strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially identical to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell.
摘要翻译： 本发明涉及用于抑制抗凋亡基因表达的双链核糖核酸（dsRNA），其包含具有长度小于25个核苷酸的核苷酸序列的互补RNA链，其至少与至少 凋亡基因的一部分，如Bcl基因。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于使用该药物组合物治疗由抗凋亡基因表达引起的疾病的方法; 以及抑制细胞中抗凋亡基因表达的方法。
-
公开(公告)号：US20080194512A1
公开(公告)日：2008-08-14
申请号：US11959936
申请日：2007-12-19
CPC分类号： C12N15/1131 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.
摘要翻译： 本发明涉及具有长度小于30个核苷酸的核苷酸序列的双链核糖核酸（dsRNA），并且其基本上与3'非翻译区（3'-UTR）的至少一部分相同 （+）链RNA病毒，例如HCV，以及包含dsRNA的药物组合物，以及药学上可接受的载体。 药物组合物可用于治疗由（+）链RNA病毒的复制或活性引起的感染和疾病以及用于抑制病毒复制的方法。
-
公开(公告)号：US07348314B2
公开(公告)日：2008-03-25
申请号：US10384512
申请日：2003-03-07
CPC分类号： C12N15/1131 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.
摘要翻译： 本发明涉及具有长度小于30个核苷酸的核苷酸序列的双链核糖核酸（dsRNA），并且其基本上与3'非翻译区（3'-UTR）的至少一部分相同 （+）链RNA病毒，例如HCV，以及包含dsRNA的药物组合物，以及药学上可接受的载体。 药物组合物可用于治疗由（+）链RNA病毒的复制或活性引起的感染和疾病以及用于抑制病毒复制的方法。
-
公开(公告)号：US08273868B2
公开(公告)日：2012-09-25
申请号：US12631689
申请日：2009-12-04
CPC分类号： C12N15/1131 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.
摘要翻译： 本发明涉及具有长度小于30个核苷酸的核苷酸序列的双链核糖核酸（dsRNA），并且其基本上与3'非翻译区（3'-UTR）的至少一部分相同 （+）链RNA病毒，例如HCV，以及包含dsRNA的药物组合物，以及药学上可接受的载体。 药物组合物可用于治疗由（+）链RNA病毒的复制或活性引起的感染和疾病以及用于抑制病毒复制的方法。
-
-
-
-
-
-
-
-
-
搜索结果
97 条记录 (耗时 0.033 秒)
